Necitumumab (proposed INN) is a monoclonal antibody and an antineoplastic. It binds to the epidermal growth factor receptor (EGFR). As of October 2009 two Phase III clinical trials are planned to investigate its effects on non-small cell lung carcinoma.
This page contains content from the copyrighted Wikipedia article "Necitumumab"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.